Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Stuart ASV., Shaw RH., Liu X., Greenland M., Aley PK., Andrews NJ., Cameron JC., Charlton S., Clutterbuck EA., Collins AM., Darton T., Dinesh T., Duncan CJA., England A., Faust SN., Ferreira DM., Finn A., Goodman AL., Green CA., Hallis B., Heath PT., Hill H., Horsington BM., Lambe T., Lazarus R., Libri V., Lillie PJ., Mujadidi YF., Payne R., Plested EL., Provstgaard-Morys S., Ramasamy MN., Ramsay M., Read RC., Robinson H., Screaton GR., Singh N., Turner DPJ., Turner PJ., Vichos I., White R., Nguyen-Van-Tam JS., Snape MD.